Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee and hip arthroplasty could be observed with the substitution of Intravenous meloxicam for ketorolac in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Treatments: Ketorolac; Meloxicam

Criteria

Inclusion Criteria:

1. Patients over the age of 18,

2. Patients undergoing primary total knee or primary total hip replacement at the University of Miami Hospital,

3. Patients that have capacity to provide medical consent

Exclusion Criteria:

1. All patients under the age of 18

2. Prisoners, diabetics, increased risk of bleeding, and pregnant women.

3. Patients with prior surgery or history of infection on the joint of interest.

4. Patients with an estimated glomerular filtration rate (eGFR) <50 ml/min

5. Patients on dialysis or renal transplant.

6. Patients on steroid preoperatively.

7. Allergy to sulfas

8. Celebrex inability to provide medical consent.

9. Any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements will exclude the participant.